Location: San Francisco, CA
CIK: 0001776382 · Show all filings
Period: Q4 2023 (← Previous) (Next →)
Filing Date: Feb 14, 2024
Total Value: $667M (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Share Price | Est. Cost/Share | Unrealized @ Report Date | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|---|
| — | RAYZEBIO INC | 5,158,162 | $321M | 48.1% | $62.17 | $22.20 | — | COM | 75525N107 |
| ALXO | ALX ONCOLOGY HLDGS INC | 9,699,925 | $144M | 21.6% | $14.89 * | $39.31 | -75.9% | COM | 00166B105 |
| PHVS | PHARVARIS N V | 4,919,504 | $138M | 20.7% | $28.05 * | $21.15 | -4.3% | COM | N69605108 |
| HRMY | HARMONY BIOSCIENCES HLDGS IN | 1,035,396 | $33.44M | 5.0% | $32.30 * | $36.46 | -23.4% | COM | 413197104 |
| — | ACELYRIN INC | 3,852,470 | $28.74M | 4.3% | $7.46 | $20.90 | — | COM | 00445A100 |
| — | ELEVATION ONCOLOGY INC | 2,914,255 | $1.565M | 0.2% | $0.54 | $9.24 | — | COM | 28623U101 |
| — | IMPEL PHARMACEUTICALS INC | 2,759,791 | $341K | 0.1% | $0.12 | $8.85 | — | COM | 45258K109 |